Amirkhani Nikan, Saraee Ehsan, Zeinalizadeh Mehdi, Fiorentino Alba, Jablonska Paola Anna, Ghalehtaki Reza
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Discov Oncol. 2025 Jul 28;16(1):1434. doi: 10.1007/s12672-025-03290-9.
Neoadjuvant stereotactic radiotherapy (NaSRT) represents a promising approach in managing brain metastases, potentially offering advantages over traditional postoperative radiotherapy.
We conducted a systematic review of the ClinicalTrials.gov website for studies investigating neoadjuvant radiotherapy for brain metastases, either as a single arm or in comparison with adjuvant radiotherapy.
This review analyzes 18 registered clinical trials investigating NaSRT, focusing on variations in trial design, inclusion criteria, and endpoints being explored. These trials aim to assess outcomes such as local control, systemic therapy integration, and the reduction of complications, including leptomeningeal disease and radiation necrosis. The diversity of methodologies underscores the need for standardized protocols to enhance comparability and future applicability.
By highlighting current trends and research gaps, this review provides insights into the evolving role of NaSRT, emphasizing its potential to influence treatment strategies and improve patient outcomes.
新辅助立体定向放射治疗(NaSRT)是治疗脑转移瘤的一种有前景的方法,可能比传统的术后放疗更具优势。
我们对ClinicalTrials.gov网站进行了系统回顾,以查找研究新辅助放疗治疗脑转移瘤的研究,这些研究可以是单臂研究,也可以是与辅助放疗进行比较的研究。
本综述分析了18项注册的研究NaSRT的临床试验,重点关注试验设计、纳入标准和所探索终点的差异。这些试验旨在评估局部控制、全身治疗整合以及并发症减少等结果,包括软脑膜疾病和放射性坏死。方法的多样性凸显了标准化方案对于提高可比性和未来适用性的必要性。
通过突出当前趋势和研究差距,本综述提供了对NaSRT不断演变的作用的见解,强调了其影响治疗策略和改善患者预后的潜力。